{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-001768","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.003870+00:00","generated_at":"2026-05-16T20:09:15.966479+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026","bullets":["Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.","Closed ~$15.7M in October equity financings and $10M August private placement, total $25.7M cash and commitments.","Plans to initiate Phase 1 clinical study of NPM-139 semaglutide implant for chronic weight management in first half 2026.","Spin-off of Cortigent temporarily withdrawn due to U.S. government shutdown; new record date expected after SEC resumes.","R&D expense $4.5M ($4.2M in Q3 2024); G&A $2.2M ($2.1M in Q3 2024); operating expenses increased $0.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-001768","json":"https://secwatch.observer/filing/0001753926-25-001768.json","markdown":"https://secwatch.observer/filing/0001753926-25-001768.md","text":"https://secwatch.observer/filing/0001753926-25-001768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625001768/0001753926-25-001768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625001768/vani-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:09:15.966479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}